Revive Therapeutics Ltd (RVVTF)

[Captain Black Bob Blanco]

Revive Therapeutics Announces Update on its Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis...

...and its Advancement of Decentralized Services Using Blockchain for Medical Cannabis Patients

TORONTO, ONTARIO--(Marketwired - Jan 4, 2018) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets, today announced an update on the Company's collaboration agreement with Chemi Pharmaceutical Inc. ("Chemi Pharma"), a Licensed Dealer for cannabis pursuant to the Controlled Drugs and Substances Act under Health Canada and its assistance with the decentralization of services enabled by blockchain technology to be integrated and utilized for the benefit of medical cannabis patients.

"Our collaboration with Chemi Pharma is an important part of our strategy in commercializing novel cannabis-based therapies and partnering with licensed producers of medical cannabis in Canada and the U.S.," said Craig Leon, Chief Executive Officer of Revive. "Revive is also evolving its concept of a patient-focused platform enabled by blockchain that integrates structured and unstructured data through the capturing of product development, clinical data, and patient information as a solution for the medical cannabis industry."

The collaboration with Chemi Pharma not only unlocks the commercialization potential of Revive's proprietary medical cannabis products, including its cannabinoid delivery technology, but also further strengthens the Company's evolving patient-focused platform. Chemi Pharma's expertise in the analytical testing of pharmaceutical products will fill the gap in the Company's patient-focused platform by validating pharma-grade medical cannabis products while advancing commercialization plans with Canadian licensed producers of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR").

Revive is currently in discussions with Canadian licensed producers of medical cannabis pursuant to ACMPR with regards to the Company's medical cannabis product pipeline and cannabinoid delivery technology. As relationships with licensed producers are solidified the Company's proposed patient-focused platform enabled by blockchain technology may offer another valuable element to the relationship. The patient-focused platform will attempt to unify all data collected from the cannabis seed, to the production and laboratory testing of the cannabis product, as well as from the patient, thus offering valuable information to licensed producers of cannabis. Furthermore, it will aim to provide the potential for personalized care by enabling patients, healthcare professionals, researchers and licensed producers of medical cannabis to collaborate, to innovate and to develop medical cannabis products in treating specific medical disorders, and to deploy individualized cannabis-based therapies based on authentic evidence of use of proprietary medical cannabis products. This is an important aspect of cannabis treatment due to the various cannabis strains and ratios that can be produced to provide optimal care to patients.